AI Boosts New Opportunities in Pharma Sector
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 03 2026
0mins
Should l Buy BMEZ?
Source: NASDAQ.COM
- Accelerated Drug Development: The application of AI is expected to reduce drug development timelines from the traditional 10-15 years to just six years, significantly enhancing pharmaceutical companies' market competitiveness and profitability, especially as faster market entry during patent protection leads to increased sales revenue.
- Emerging Investment Opportunity: The BlackRock Health Sciences Term Trust (BMEZ) is currently trading at an 11.4% discount, offering an attractive 8.8% dividend, appealing to investors looking for long-term gains driven by AI, despite the market's low focus on the pharmaceutical sector.
- Gilead's AI Investment: Gilead Sciences is ramping up its AI investments by constructing a 180,000-square-foot AI research center, which is expected to accelerate its R&D progress in oncology and HIV treatments, further solidifying its market position.
- Market Rebound Potential: BMEZ's discount has widened from 3% a year ago to 11.4%, indicating a market misunderstanding of the pharmaceutical sector; if the discount returns to historical levels, investors could see about a 10% price upside, combined with dividends, leading to an overall return of around 18%.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BMEZ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BMEZ
About BMEZ
BlackRock Health Sciences Term Trust (the Trust) is a closed-end management investment trust. The Trust’s investment objectives are to provide total return and income through a combination of current income, current gains, and long-term capital appreciation. The Trust invests at least 80% of its total assets in equity securities of companies principally engaged in the health sciences group of industries and equity derivatives with exposure to the health sciences group of industries. Trust may also invest in companies of any market capitalization located anywhere in the world, including companies located in emerging markets. The Trust focuses on small and mid-sized healthcare companies. The Trust invests in industries, such as biotechnology, life sciences tools and services, pharmaceuticals, diversified financial services, health care technology, and others. The Trust’s investment adviser is BlackRock Advisors, LLC.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AI Boosts New Opportunities in Pharma Sector
- Accelerated Drug Development: The application of AI is expected to reduce drug development timelines from the traditional 10-15 years to just six years, significantly enhancing pharmaceutical companies' market competitiveness and profitability, especially as faster market entry during patent protection leads to increased sales revenue.
- Emerging Investment Opportunity: The BlackRock Health Sciences Term Trust (BMEZ) is currently trading at an 11.4% discount, offering an attractive 8.8% dividend, appealing to investors looking for long-term gains driven by AI, despite the market's low focus on the pharmaceutical sector.
- Gilead's AI Investment: Gilead Sciences is ramping up its AI investments by constructing a 180,000-square-foot AI research center, which is expected to accelerate its R&D progress in oncology and HIV treatments, further solidifying its market position.
- Market Rebound Potential: BMEZ's discount has widened from 3% a year ago to 11.4%, indicating a market misunderstanding of the pharmaceutical sector; if the discount returns to historical levels, investors could see about a 10% price upside, combined with dividends, leading to an overall return of around 18%.
See More
BlackRock Closed-End Funds Distribution Announcement
- Distribution Frequency Change: Certain BlackRock closed-end funds have announced a shift from monthly to quarterly distributions to enhance visibility on future payouts, thereby boosting investor confidence and optimizing liquidity.
- Distribution Amount Overview: For instance, the BlackRock Municipal 2030 Target Term Trust (BTT) has a monthly distribution of $0.046400, indicating stable cash flow that is expected to attract more investors seeking reliable income.
- Managed Distribution Plan: The BlackRock Capital Allocation Term Trust (BCAT) and BlackRock ESG Capital Allocation Term Trust (ECAT) have adopted a managed distribution plan to ensure a monthly distribution rate of 20% of each fund's 12-month rolling average net asset value, maintaining investor yield expectations.
- Tax Compliance Notices: All funds have sent Section 19 notices to shareholders to comply with the Investment Company Act of 1940, enhancing transparency and assisting investors in understanding the sources and tax characteristics of distributions.
See More
BlackRock Funds Announce 2026 Distribution Plans
- Distribution Amounts Announced: BlackRock's various funds announced distributions for February 27, 2026, with BCX distributing $0.0697 per share and BME distributing $0.2621 per share, indicating the company's ongoing cash flow and profitability.
- Managed Distribution Plan: All funds have adopted a managed distribution plan to ensure stable monthly distributions, with BCAT and ECAT's distributions based on 20% of their 12-month rolling average net asset value, reflecting the company's robust capital management strategy.
- Transparent Sources of Income: The sources of distributions for each fund include net income, short-term, and long-term capital gains, with BCX's distribution being 100% return of capital, showcasing its adaptability in the current market environment.
- Increased Investor Confidence: The distribution plans and transparent income sources of BlackRock funds are expected to enhance investor confidence, promote capital inflows, and further support the company's long-term growth strategy.
See More
Announcement of Distribution Dates and Amounts for Specific BlackRock Closed-End Funds
Distribution Dates Announced: Specific distribution dates for certain BlackRock closed-end funds have been announced.
Amounts Specified: The announcement includes details on the amounts to be distributed for these funds.
See More
BLACKROCK CLOSED-END FUNDS DISCLOSE ESTIMATED DISTRIBUTION SOURCES
BlackRock Closes End Funds: BlackRock has announced the closure of certain end funds, indicating a strategic shift in their investment approach.
Estimated Sources of Distributions: The announcement includes details on the estimated sources of distributions for the affected funds, providing transparency to investors.
See More
BlackRock Funds Announce 2026 Distribution Plans
- Distribution Amounts Announced: BlackRock's various funds announced per-share distributions for January 30, 2026, with BCX at $0.0697 and BME at $0.2621, reflecting the company's ongoing commitment to stable income distribution.
- Managed Distribution Plan: All funds have adopted a managed distribution plan to ensure monthly distributions of income, capital gains, or return of capital, aimed at providing investors with consistent cash flow and enhancing investor confidence.
- Transparent Sources of Income: As of January 30, 2026, the sources of distributions for each fund include net income and return of capital, with 76% of BCX's distribution coming from capital return, indicating a diverse income structure.
- Long-term Investment Strategy: The distribution plans of BlackRock funds are expected to exceed current income and capital gains, potentially including return of capital, demonstrating the company's strategic flexibility in managing market volatility and maintaining investor returns.
See More
AI Boosts New Opportunities in Pharma Sector
- Accelerated Drug Development: The application of AI is expected to reduce drug development timelines from the traditional 10-15 years to just six years, significantly enhancing pharmaceutical companies' market competitiveness and profitability, especially as faster market entry during patent protection leads to increased sales revenue.
- Emerging Investment Opportunity: The BlackRock Health Sciences Term Trust (BMEZ) is currently trading at an 11.4% discount, offering an attractive 8.8% dividend, appealing to investors looking for long-term gains driven by AI, despite the market's low focus on the pharmaceutical sector.
- Gilead's AI Investment: Gilead Sciences is ramping up its AI investments by constructing a 180,000-square-foot AI research center, which is expected to accelerate its R&D progress in oncology and HIV treatments, further solidifying its market position.
- Market Rebound Potential: BMEZ's discount has widened from 3% a year ago to 11.4%, indicating a market misunderstanding of the pharmaceutical sector; if the discount returns to historical levels, investors could see about a 10% price upside, combined with dividends, leading to an overall return of around 18%.
See More
BlackRock Closed-End Funds Distribution Announcement
- Distribution Frequency Change: Certain BlackRock closed-end funds have announced a shift from monthly to quarterly distributions to enhance visibility on future payouts, thereby boosting investor confidence and optimizing liquidity.
- Distribution Amount Overview: For instance, the BlackRock Municipal 2030 Target Term Trust (BTT) has a monthly distribution of $0.046400, indicating stable cash flow that is expected to attract more investors seeking reliable income.
- Managed Distribution Plan: The BlackRock Capital Allocation Term Trust (BCAT) and BlackRock ESG Capital Allocation Term Trust (ECAT) have adopted a managed distribution plan to ensure a monthly distribution rate of 20% of each fund's 12-month rolling average net asset value, maintaining investor yield expectations.
- Tax Compliance Notices: All funds have sent Section 19 notices to shareholders to comply with the Investment Company Act of 1940, enhancing transparency and assisting investors in understanding the sources and tax characteristics of distributions.
See More
BlackRock Funds Announce 2026 Distribution Plans
- Distribution Amounts Announced: BlackRock's various funds announced distributions for February 27, 2026, with BCX distributing $0.0697 per share and BME distributing $0.2621 per share, indicating the company's ongoing cash flow and profitability.
- Managed Distribution Plan: All funds have adopted a managed distribution plan to ensure stable monthly distributions, with BCAT and ECAT's distributions based on 20% of their 12-month rolling average net asset value, reflecting the company's robust capital management strategy.
- Transparent Sources of Income: The sources of distributions for each fund include net income, short-term, and long-term capital gains, with BCX's distribution being 100% return of capital, showcasing its adaptability in the current market environment.
- Increased Investor Confidence: The distribution plans and transparent income sources of BlackRock funds are expected to enhance investor confidence, promote capital inflows, and further support the company's long-term growth strategy.
See More
Announcement of Distribution Dates and Amounts for Specific BlackRock Closed-End Funds
Distribution Dates Announced: Specific distribution dates for certain BlackRock closed-end funds have been announced.
Amounts Specified: The announcement includes details on the amounts to be distributed for these funds.
See More
BLACKROCK CLOSED-END FUNDS DISCLOSE ESTIMATED DISTRIBUTION SOURCES
BlackRock Closes End Funds: BlackRock has announced the closure of certain end funds, indicating a strategic shift in their investment approach.
Estimated Sources of Distributions: The announcement includes details on the estimated sources of distributions for the affected funds, providing transparency to investors.
See More
BlackRock Funds Announce 2026 Distribution Plans
- Distribution Amounts Announced: BlackRock's various funds announced per-share distributions for January 30, 2026, with BCX at $0.0697 and BME at $0.2621, reflecting the company's ongoing commitment to stable income distribution.
- Managed Distribution Plan: All funds have adopted a managed distribution plan to ensure monthly distributions of income, capital gains, or return of capital, aimed at providing investors with consistent cash flow and enhancing investor confidence.
- Transparent Sources of Income: As of January 30, 2026, the sources of distributions for each fund include net income and return of capital, with 76% of BCX's distribution coming from capital return, indicating a diverse income structure.
- Long-term Investment Strategy: The distribution plans of BlackRock funds are expected to exceed current income and capital gains, potentially including return of capital, demonstrating the company's strategic flexibility in managing market volatility and maintaining investor returns.
See More
